XM does not provide services to residents of the United States of America.


Trade Ideas

Traders Sentiment

Technical Summary



U.S. STOCKS Hyatt Hotels, Morningstar Inc, SunPower Corp

BUZZ-U.S. STOCKS ON THE MOVE-Hyatt Hotels, Morningstar Inc, SunPower Corp Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes lost momentum on Friday following a dizzying rally fueled by euphoria around artificial intelligence that briefly vaulted Nvidia to over $2 trillion in market valuation for the first time.

BioMarin climbs after Q4 revenue beat

BUZZ-BioMarin climbs after Q4 revenue beat ** Shares of therapy developer BioMarin Pharmaceutical BMRN.O rise ~1% to $90.87 ** Company's quarterly revenue of $646.2 mln beats analysts' average expectation of $636.9 mln - LSEG data ** Says revenue for its dwarfism therapy Voxzogo grew 18% over the prior quarter, positively impacted by an increase in prescriptions for children under the age of 5 in the U.S.

U.S. Biomarin Pharmaceutical, Intuit, Penumbra

U.S. RESEARCH ROUNDUP-Biomarin Pharmaceutical, Intuit, Penumbra Feb 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biomarin Pharmaceutical, Intuit and Penumbra, on Friday. HIGHLIGHTS * American Woodmark Corp AMWD.O : Baird raises to outperform rating * Biomarin Pharmaceutical Inc BMRN.O : Piper Sandler cuts target price to $107 from $115 * Fluence Energy Inc FLNC.O : JP Morgan raises to overweight from neutral *

Biomarin Pharmaceutical Inc reports results for the quarter ended in December - Earnings Summary

Biomarin Pharmaceutical Inc reports results for the quarter ended in December - Earnings Summary Biomarin Pharmaceutical Inc BMRN.OQ reported quarterly adjusted earnings of 18 cents​​ per share for the quarter ended in December, higher than the same quarter last year, when the company reported breakeven earnings per share. The mean expectation of twenty five analysts for the quarter was for earnings of 23 cents per share.

Biomarin Pharmaceutical Q4 EPS USD 0.11

BRIEF-Biomarin Pharmaceutical Q4 EPS USD 0.11 Feb 22 (Reuters) - Biomarin Pharmaceutical Q4 revenue USD 646.2 million vs. IBES estimate USD 636.9 million. Q4 adjusted EPS USD 0.49 Q4 net income USD 20.4 million


Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.